These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15456939)

  • 1. Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine.
    Parekh-Olmedo H; Wang J; Gusella JF; Kmiec EB
    J Mol Neurosci; 2004; 24(2):257-67. PubMed ID: 15456939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.
    Skogen M; Roth J; Yerkes S; Parekh-Olmedo H; Kmiec E
    BMC Neurosci; 2006 Oct; 7():65. PubMed ID: 17014717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
    Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
    Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity.
    Kaytor MD; Wilkinson KD; Warren ST
    J Neurochem; 2004 May; 89(4):962-73. PubMed ID: 15140195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
    Hazeki N; Nakamura K; Goto J; Kanazawa I
    Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
    Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ
    Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
    Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S
    Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
    Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
    Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues.
    Chiang MC; Lee YC; Huang CL; Chern Y
    J Biol Chem; 2005 Apr; 280(14):14331-40. PubMed ID: 15689617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.
    Muchowski PJ; Ning K; D'Souza-Schorey C; Fields S
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):727-32. PubMed ID: 11792857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
    Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
    Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.
    Lee WC; Yoshihara M; Littleton JT
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3224-9. PubMed ID: 14978262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
    Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
    Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions.
    Davranche A; Aviolat H; Zeder-Lutz G; Busso D; Altschuh D; Trottier Y; Klein FA
    Hum Mol Genet; 2011 Jul; 20(14):2795-806. PubMed ID: 21518730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntingtin processing in pathogenesis of Huntington disease.
    Qin ZH; Gu ZL
    Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase.
    Scappini E; Koh TW; Martin NP; O'Bryan JP
    Hum Mol Genet; 2007 Aug; 16(15):1862-71. PubMed ID: 17550941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.